Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy

• Published in: Biomedicines Vol. 10; no. 4; p. 910
• Main Authors: Chung, Jae-Hoon, Lee, Chung-Un, Lee, Dong-Hyeon, Song, Wan
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15.04.2022; MDPI
• Subjects: Apoptosis; Cancer; Chemotherapy; Histology; Immunohistochemistry; Immunotherapy; Laboratories; Medical prognosis; Metastasis; micropapillary variant; Patients; PD-L1 protein; programmed death ligand-1; recurrence; squamous differentiation; Statistical analysis; Survival analysis; Tumor-infiltrating lymphocytes; Urothelial carcinoma; United States > US; micropapillary variant; recurrence; urothelial carcinoma; programmed death ligand-1; squamous differentiation
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10040910

The expression and prognostic role of programmed death ligand-1 (PD-L1) on tumor-infiltrating immune cells (TICs) has not been determined in urothelial carcinoma (UC) with variant histology. We retrospectively reviewed 90 patients (44 with micropapillary variant of UC (MPUC) and 46 with UC with squamous differentiation (UCSD)) who underwent radical cystectomy between January 2013 and December 2019. The expression of PD-L1 in TICs was measured using the VENTANA (SP-142) immunohistochemistry assay and dichotomized using a 5% cutoff value (positive ≥ 5%). Kaplan-Meier survival analysis was used to estimate recurrence-free survival (RFS), and multivariable Cox proportional hazard models were used to identify factors predicting tumor recurrence. Overall, positive PD-L1 expression in TICs was confirmed in 50 of 90 (55.6%) patients (40.1% (18/44) of MPUC and 69.9% (32/46) of UCSD). RFS was significantly shorter in patients with positive PD-L1 expression in TICs than in those with negative PD-L1 expression both in MPUC ( = 0.005) and UCSD ( = 0.046). Positive PD-L1 expression in TICs was significantly associated with an increased risk of tumor recurrence in both MPUC (HR = 1.85; 95% CI: 1.323-2.672; = 0.017) and UCSD (HR = 1.58; 95% CI: 1.162-2.780; = 0.032). In conclusion, positive PD-L1 expression in TICs was significantly associated with poorer RFS in both MPUC and UCSD patients. Our results support the use of adjuvant immunotherapy in these patients if they test positive for PD-L1 in their TICs.